FDA Drug Safety Podcast: FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
On November 29, 2018 FDA is warning that signs and symptoms of a life-threatening side effect called differentiation syndrome are not being recognized in patients receiving the acute myeloid leukemia medicine Idhifa, active ingredient enasidenib.
Source: FDA Drug Safety Podcasts - Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
More News: Acute Leukemia | Acute Myeloid Leukemia | Drugs & Pharmacology | Food and Drug Administration (FDA) | Leukemia | Podcasts | Warnings